PE20010801A1 - Dispositivos para el suministro de farmacos que tienen propiedades antiprogestinicas - Google Patents

Dispositivos para el suministro de farmacos que tienen propiedades antiprogestinicas

Info

Publication number
PE20010801A1
PE20010801A1 PE2000001367A PE0013672000A PE20010801A1 PE 20010801 A1 PE20010801 A1 PE 20010801A1 PE 2000001367 A PE2000001367 A PE 2000001367A PE 0013672000 A PE0013672000 A PE 0013672000A PE 20010801 A1 PE20010801 A1 PE 20010801A1
Authority
PE
Peru
Prior art keywords
antiprogestinal
drugs
delivery
properties
units
Prior art date
Application number
PE2000001367A
Other languages
English (en)
Spanish (es)
Inventor
Jarkko Ruohonen
Matti Lehtinen
Harri Jukarainen
Tommi Markkula
Juha Ala-Sorvari
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of PE20010801A1 publication Critical patent/PE20010801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/04—Polysiloxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
    • C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
    • C08L83/12—Block- or graft-copolymers containing polysiloxane sequences containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/04—Polysiloxanes
    • C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
    • C08G77/18—Polysiloxanes containing silicon bound to oxygen-containing groups to alkoxy or aryloxy groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/44—Block-or graft-polymers containing polysiloxane sequences containing only polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/42—Block-or graft-polymers containing polysiloxane sequences
    • C08G77/46—Block-or graft-polymers containing polysiloxane sequences containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/48—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms
    • C08G77/50—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/70—Siloxanes defined by use of the MDTQ nomenclature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PE2000001367A 1999-12-23 2000-12-19 Dispositivos para el suministro de farmacos que tienen propiedades antiprogestinicas PE20010801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/472,126 US6476079B1 (en) 1999-12-23 1999-12-23 Devices for the delivery of drugs having antiprogestinic properties

Publications (1)

Publication Number Publication Date
PE20010801A1 true PE20010801A1 (es) 2001-08-09

Family

ID=23874296

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001367A PE20010801A1 (es) 1999-12-23 2000-12-19 Dispositivos para el suministro de farmacos que tienen propiedades antiprogestinicas

Country Status (31)

Country Link
US (1) US6476079B1 (cg-RX-API-DMAC7.html)
EP (1) EP1239829B1 (cg-RX-API-DMAC7.html)
JP (1) JP4895150B2 (cg-RX-API-DMAC7.html)
KR (1) KR100850548B1 (cg-RX-API-DMAC7.html)
CN (1) CN100346772C (cg-RX-API-DMAC7.html)
AR (1) AR026647A1 (cg-RX-API-DMAC7.html)
AT (1) ATE401859T1 (cg-RX-API-DMAC7.html)
AU (1) AU781555B2 (cg-RX-API-DMAC7.html)
BR (1) BR0016697A (cg-RX-API-DMAC7.html)
CA (1) CA2395226C (cg-RX-API-DMAC7.html)
CO (1) CO5261571A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301865B6 (cg-RX-API-DMAC7.html)
DE (2) DE60039626D1 (cg-RX-API-DMAC7.html)
DK (1) DK1239829T3 (cg-RX-API-DMAC7.html)
EE (1) EE05123B1 (cg-RX-API-DMAC7.html)
ES (1) ES2310526T3 (cg-RX-API-DMAC7.html)
HK (1) HK1047235B (cg-RX-API-DMAC7.html)
HU (1) HU229438B1 (cg-RX-API-DMAC7.html)
IL (2) IL149663A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02006174A (cg-RX-API-DMAC7.html)
NO (1) NO332261B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ519876A (cg-RX-API-DMAC7.html)
PE (1) PE20010801A1 (cg-RX-API-DMAC7.html)
PL (1) PL201216B1 (cg-RX-API-DMAC7.html)
PT (1) PT1239829E (cg-RX-API-DMAC7.html)
RU (1) RU2228170C2 (cg-RX-API-DMAC7.html)
SK (1) SK287229B6 (cg-RX-API-DMAC7.html)
TW (1) TWI248367B (cg-RX-API-DMAC7.html)
UA (1) UA70401C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001047490A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200203620B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887948B2 (en) * 1998-06-30 2005-05-03 Schering Oy Method for preparing a siloxane-based elastomer composition
US6794464B2 (en) 1998-06-30 2004-09-21 Schering Oy Membrane or matrix for controlling the permeation rate of drugs
WO2002032433A1 (en) * 2000-10-20 2002-04-25 Leiras Oy Drug delivery system
CA2457979A1 (en) * 2001-08-31 2003-03-06 Schering Oy A delivery system
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
SI1696822T1 (sl) * 2003-11-13 2010-07-30 Psivida Inc Injektibilen implantat z zadržanim sproščanjem, ki ima bioerodibilno matično jedro in bioerodibilno kožo
RU2283637C1 (ru) * 2005-03-22 2006-09-20 Общество с ограниченной ответственностью "Производственно-коммерческая фирма "Две линии" Пластырь
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
KR101377900B1 (ko) 2005-10-13 2014-03-27 신세스 게엠바하 약물-함침 용기
US20070149916A1 (en) * 2005-12-22 2007-06-28 Alza Corporation Dry matrices as drug reservoirs in electrotransport applications
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
DE102007032468A1 (de) * 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
EP2057972A1 (en) * 2007-11-07 2009-05-13 N.V. Organon Intrauterine deposit
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US11992431B2 (en) 2008-09-17 2024-05-28 Bayer Oy Inserter
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
WO2010031902A1 (en) 2008-09-17 2010-03-25 Bayer Schering Pharma Oy An inserter
CA2738880A1 (en) * 2008-11-06 2010-05-14 Novo Nordisk A/S Electronically assisted drug delivery device
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8569421B2 (en) 2009-04-23 2013-10-29 ATRP Solutions, Inc. Star macromolecules for personal and home care
US8568374B2 (en) * 2009-05-04 2013-10-29 Merck Sharp & Dohme B.V. Intrauterine system
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
JP5894143B2 (ja) * 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
BR112014001450A2 (pt) * 2011-07-20 2017-07-18 F Kiser Patrick dispositivos intravaginais para distribuição de droga
TWI590843B (zh) 2011-12-28 2017-07-11 信迪思有限公司 膜及其製造方法
CA2882832C (en) 2012-08-30 2021-08-24 ATRP Solutions, Inc. Dual mechanism thickening agents for hydraulic fracturing fluids
EP2951220B1 (en) 2013-02-04 2020-11-25 Pilot Polymer Technologies, Inc. Salt-tolerant star macromolecules
EP2953678B1 (en) 2013-02-06 2020-03-25 Sillender, Mark Therapeutic substance transfer catheter
AU2014214538B2 (en) 2013-02-06 2018-11-15 Mark SILLENDER Embryo transfer catheter and method
WO2014160305A1 (en) * 2013-03-14 2014-10-02 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates and silicon-based linkers
ES2708351T3 (es) 2013-04-11 2019-04-09 Bayer Pharma AG Forma de dosificación de un antagonista del receptor de progesterona
JP6456935B2 (ja) 2013-06-21 2019-01-23 デピュイ・シンセス・プロダクツ・インコーポレイテッド フィルム及び製造方法
WO2015023811A2 (en) 2013-08-16 2015-02-19 The J. David Gladstone Institutes Compositions and methods for identifying latently infected cells
EP2982352B1 (en) * 2014-06-28 2018-10-03 Laboratorios Andrómaco S.A. Cervical pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth
JP6689210B2 (ja) 2014-07-03 2020-04-28 パイロット ポリマー テクノロジーズ， インク． 界面活性剤相溶性星形高分子
EP3206751A4 (en) 2014-10-14 2018-06-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
CN107406677A (zh) * 2015-03-05 2017-11-28 道康宁东丽株式会社 可固化有机聚硅氧烷组合物、其用途以及由该组合物制备的层合体
EP3294300B1 (en) * 2015-05-13 2024-12-18 Bayer Oy Long acting drug delivery device in form of an implant or iud comprising levonorgestrel and ethinylestradiol
CN106546705B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 一种脂质体药物体外释放的测试方法
CN106546706B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 pH梯度主动载药法制备的脂质体药物的体外释放测试方法
MX385367B (es) 2016-06-07 2025-03-18 The J David Gladstone Inst Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3840749B1 (en) 2018-08-22 2023-08-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compounds for treating cardiac valve disease
WO2020252305A1 (en) 2019-06-14 2020-12-17 The J. David Gladstone Institutes, A Testamentary Trust Establishe Under The Will Of J. David Gladstone Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle
US10918649B2 (en) * 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
TWI803052B (zh) * 2021-11-12 2023-05-21 佛教慈濟醫療財團法人 經皮遞送裝置及其使用及製造方法
US20230263724A1 (en) * 2022-02-22 2023-08-24 Celanese Eva Performance Polymers Llc Intravaginal Ring Device for the Delivery of Aromatase Inhibitor
CN119662025A (zh) * 2023-09-13 2025-03-21 沈阳药科大学 硅胶材料及其制备方法、硅胶管和埋植剂及其制备方法、应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
JPS519003B1 (cg-RX-API-DMAC7.html) * 1970-11-07 1976-03-23
US3836560A (en) 1971-03-08 1974-09-17 Union Carbide Corp Organosilicone polymers
US4155991A (en) * 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US4323488A (en) * 1979-03-26 1982-04-06 Shin-Etsu Chemical Company Limited Method for the preparation of silicone-modified polyoxyalkylene polyethers and room temperature-curable compositions therewith
JPS60148560A (ja) * 1984-01-17 1985-08-05 富士システムズ株式会社 皮膚用封止材
US4600751A (en) * 1984-12-18 1986-07-15 Dow Corning Corporation Hydrophilic silicone-organic copolymer elastomers
CA1257727A (en) * 1984-12-18 1989-07-18 Chi-Long Lee Hydrophilic silicone-organic copolymer elastomers
GB8704755D0 (en) * 1987-02-28 1987-04-01 Dow Corning Ltd Pharmaceutical delivery device
US4951657A (en) * 1988-04-22 1990-08-28 Dow Corning Corporation Heat sealable membrane for transdermal drug release
EP0545002A1 (en) 1991-11-21 1993-06-09 Kose Corporation Silicone polymer, paste-like composition and water-in-oil type cosmetic composition comprising the same
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
JP3201940B2 (ja) * 1995-09-12 2001-08-27 信越化学工業株式会社 硬化性シリコーンエラストマー組成物及びその製造方法
US5811487A (en) * 1996-12-16 1998-09-22 Dow Corning Corporation Thickening silicones with elastomeric silicone polyethers
US5889108A (en) 1997-06-02 1999-03-30 Dow Corning Corporation Thickening solvents with elastomeric silicone polyethers
US6013711A (en) 1997-06-18 2000-01-11 Ck Witco Corporation Hydrophilic polysiloxane compositions
FI103051B1 (fi) 1997-08-22 1999-04-15 Leiras Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens

Also Published As

Publication number Publication date
SK7012002A3 (en) 2003-01-09
KR100850548B1 (ko) 2008-08-06
NO332261B1 (no) 2012-08-13
UA70401C2 (uk) 2004-10-15
DE1239829T1 (de) 2003-02-06
CZ20022106A3 (cs) 2002-11-13
ATE401859T1 (de) 2008-08-15
MXPA02006174A (es) 2002-12-05
ES2310526T3 (es) 2009-01-16
AR026647A1 (es) 2003-02-19
NO20023012L (no) 2002-08-09
TWI248367B (en) 2006-02-01
PL355994A1 (en) 2004-05-31
US6476079B1 (en) 2002-11-05
SK287229B6 (sk) 2010-03-08
AU781555B2 (en) 2005-06-02
DE60039626D1 (de) 2008-09-04
CN100346772C (zh) 2007-11-07
CN1420762A (zh) 2003-05-28
DK1239829T3 (da) 2008-11-24
IL149663A (en) 2007-02-11
WO2001047490A1 (en) 2001-07-05
HK1047235A1 (en) 2003-02-14
PT1239829E (pt) 2008-10-09
RU2002119587A (ru) 2004-02-27
HU229438B1 (hu) 2013-12-30
KR20020067573A (ko) 2002-08-22
CA2395226C (en) 2009-01-27
CO5261571A1 (es) 2003-03-31
HK1047235B (en) 2009-04-24
RU2228170C2 (ru) 2004-05-10
NZ519876A (en) 2004-02-27
CA2395226A1 (en) 2001-07-05
CZ301865B6 (cs) 2010-07-14
EP1239829A1 (en) 2002-09-18
HUP0204015A3 (en) 2004-06-28
PL201216B1 (pl) 2009-03-31
HUP0204015A2 (en) 2003-05-28
EP1239829B1 (en) 2008-07-23
BR0016697A (pt) 2002-09-03
NO20023012D0 (no) 2002-06-21
JP2003518482A (ja) 2003-06-10
AU1710201A (en) 2001-07-09
EE200200349A (et) 2003-08-15
JP4895150B2 (ja) 2012-03-14
IL149663A0 (en) 2002-11-10
ZA200203620B (en) 2003-07-30
EE05123B1 (et) 2009-02-16

Similar Documents

Publication Publication Date Title
PE20010801A1 (es) Dispositivos para el suministro de farmacos que tienen propiedades antiprogestinicas
PE20030316A1 (es) Sistema de suministro de dos o mas agentes terapeuticamente activos
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
DE60231862D1 (de) Erodierbare polymere zur injektion
AR018952A1 (es) Una membrana o matriz para controlar la velocidad de penetracion de farmacos
DE69923786D1 (de) Dünner polymerfilm als medikamentenreservoir
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR045039A1 (es) Dispositivo de administracion de drogas oftalmicas
AR036746A1 (es) Productos en gel para la axila, con componente de bloque de agua
ES2188787T3 (es) Compuesto medicamentoso de micela copolimera y metodo para su preparacion.
PE20001041A1 (es) Dispositivo de suministro de farmacos, especialmente para el suministro de progestinas y estrogenos
AR109808A1 (es) Prepolímeros tri-bloque y su uso en hidrogeles siliconados
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
DE60044459D1 (de) IN ORGANISCHEN LÖSEMITTELN LÖSLICHE BIOLOGISCH ABBAUBARE POLY (ALKYLENOXID)- POLY (p-DIOXANON) BLOCKCOPOLYMERE SOWIE DIESE ENTHALTENDE ZUSAMMENSETZUNG ZUR ARZNEISTOFFVERABREICHUNG
GT199900203A (es) Composiciones de celecoxib.
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
PA8584101A1 (es) Composicion antihelmintica e inyectable mejoradora de crecimiento
AR046842A1 (es) Excipientes en vehiculos de administracion de farmaco
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
BR0111869A (pt) Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear
PE20060244A1 (es) Formulacion farmaceutica de deposito que contiene polietilenglicol de peso molecular menor a 600 daltones
AR029941A1 (es) Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
GT200000214A (es) Auxiliar humectante concentrado pobre en espuma, su empleo y procedimiento para su elaboracion.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed